Cresco Labs Inc. (OTCMKTS:CRLBF) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Cresco Labs Inc. (OTCMKTS:CRLBF) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $2.50.

Several equities research analysts have issued reports on the stock. Cormark lowered shares of Cresco Labs from a “moderate buy” rating to a “hold” rating in a report on Monday, November 11th. Atb Cap Markets lowered shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. Finally, Roth Capital raised shares of Cresco Labs to a “strong-buy” rating in a report on Sunday, November 10th.

Cresco Labs Trading Down 11.6 %

Shares of Cresco Labs stock opened at $0.73 on Wednesday. The firm has a market capitalization of $353.90 million, a PE ratio of -3.63 and a beta of 1.79. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.97 and a quick ratio of 1.39. The company’s fifty day moving average price is $0.91 and its two-hundred day moving average price is $1.25. Cresco Labs has a 52-week low of $0.73 and a 52-week high of $2.60.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.